1 The Duke Clinical Research Institute Duke University Medical Center Durham NC.
J Am Heart Assoc. 2019 Apr 16;8(8):e011322. doi: 10.1161/JAHA.118.011322.
Background Hospitalization for acute myocardial infarction (MI) in the United States is both common and expensive, but those features alone provide little insight into cost-saving opportunities. Methods and Results To understand the cost drivers during hospitalization for acute MI and in the following year, we prospectively studied 11 969 patients with acute MI undergoing percutaneous coronary intervention at 233 US hospitals (2010-2013) from the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) registry. Baseline costs were collected in a random subset (n=4619 patients, 54% ST-segment-elevation MI [STEMI]), while follow-up costs out to 1 year were collected for all patients. The mean index length of stay was 3.1 days (for both STEMI and non-STEMI) and mean intensive care unit length of stay was 1.2 days (1.4 days for STEMI and 1.0 days for non-STEMI). Index hospital costs averaged $18 931 ($19 327 for STEMI, $18 465 for non-STEMI), with 45% catheterization laboratory-related and 20% attributable to postprocedure hospital stay. Patient factors, including severity of illness and extent of coronary disease, and hospital characteristics, including for profit status and geographic region, identified significant variations in cost. Intensive care was used for 53% of non-STEMI and increased costs by $3282. Postdischarge 1-year costs averaged $8037, and 48% of patients were rehospitalized (half within 2 months and 57% with a cardiovascular diagnosis). Conclusions While much of the cost of patients with acute MI treated with percutaneous coronary intervention is probably not modifiable by the care team, cost reductions are still possible through quality-preserving practice efficiencies, such as need-based use rather than routine use of intensive care unit for patients with stable non-STEMI. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT00097591.
背景 美国因急性心肌梗死(MI)住院的情况既常见又昂贵,但仅这些特征并不能提供多少节省成本的机会。
方法和结果 为了了解急性 MI 住院期间和随后一年的成本驱动因素,我们前瞻性地研究了 2010-2013 年在 233 家美国医院接受经皮冠状动脉介入治疗的 11969 例急性 MI 患者(TRANSLATE-ACS [ADP 受体抑制剂治疗:急性冠状动脉综合征后治疗模式和事件的纵向评估]登记处)。在一个随机亚组(n=4619 例患者,54%ST 段抬高心肌梗死[STEMI])中收集基线费用,而所有患者均收集随访至 1 年的费用。平均住院日为 3.1 天(STEMI 和非-STEMI 均如此),重症监护病房住院日平均为 1.2 天(STEMI 为 1.4 天,非-STEMI 为 1.0 天)。医院平均指数住院费用为 18931 美元(STEMI 为 19327 美元,非-STEMI 为 18465 美元),其中 45%与导管室相关,20%归因于术后住院。患者因素,包括疾病严重程度和冠状动脉疾病程度,以及医院特征,包括营利性和地理位置,确定了成本的显著差异。非-STEMI 患者中有 53%使用了重症监护,费用增加了 3282 美元。出院后 1 年的费用平均为 8037 美元,48%的患者再次住院(一半在 2 个月内,57%有心血管诊断)。
结论 虽然接受经皮冠状动脉介入治疗的急性 MI 患者的大部分费用可能无法通过护理团队改变,但仍可以通过保持质量的实践效率来降低成本,例如根据需要使用重症监护病房,而不是常规用于稳定的非-STEMI 患者。
https://www.clinicaltrials.gov。
NCT00097591。